An important consideration in developing standards and regulations that govern the production and use of commercial nanoscale materials is the development of robust and reliable measurements to monitor the potential adverse biological effects of such products. These measurements typically require cell-based and other biological assays that provide an assessment of the risks associated with the nanomaterial of interest. In this report, we describe the use of cause-and-effect (C&E) analysis to design robust, high quality cell-based assays to test nanoparticle related-cytotoxicity. C&E analysis of an assay system identifies the sources of variability that influence the test result. These sources can then be used to design control experiments that aid in establishing the validity of a test result. We demonstrate the application of C&E analysis to the commonly used 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) cell-viability assay. This is the first time to our knowledge that C&E analysis has been used to characterize a cell-based toxicity assay.
Introduction
Engineered nanomaterials (ENMs) are manufactured nanoparticles often with unique physico-chemical properties when compared to bulk materials. These unique properties such as high surface reactivity and quantum confinement will allow ENM to play a role in a variety of commercial applications such as for textiles, environmental remediation, and medicine. [1] [2] [3] [4] [5] However, these same properties may also result in ENMs having unintended and potentially harmful effects on ecological receptors or humans during the manufacturing, use, and disposal of nanomaterial-enabled products. [6] [7] [8] It is important to be able to accurately assess the effects of nanomaterials on biological systems to inform risk-benefit models that guide how to regulate these specialized materials.
A tiered testing approach similar to that used for chemical compound testing 9, 10 has been proposed for assessing potential hazard associated with ENM. 11, 12 The approach starts with cell-based toxicity assays as rapid screening tools and suggests further testing based on the screening results, the exposure mode, and the physicochemical characteristics of the ENM. 13 However, this approach requires the availability of cheap, reliable and well-controlled cell-based assays to assess ENM-biological system interactions. Unfortunately, different laboratories often obtain substantially differing results when testing cellular interactions with ENMs. 14 For example, the reported effects of nanoparticulate TiO2, carbon nanotubes (CNT), silica and ZnO nanoparticles on cellular systems appear contradictory. [15] [16] [17] [18] Uncontrolled conditions such as laboratory lighting or interference with toxicity assay readouts have been shown to affect assay results for ENM (i.e., TiO2, CNT). [19] [20] [21] [22] [23] Moreover, a literature survey of nanomaterial toxicity papers using biochemical techniques published since 2010 5 revealed that approximately 95 % of these papers did not account for ENM interferences. 24 Incomparability of data for the effects of ENM on cells can result from poorly defined information on dosage, as well as differences in assay procedures, poor information on assay system performance and weak or absent assay quality control experiments. 14 Physico-chemical properties of the ENM, such as composition, size, shape, crystal structure, coating, and dissolution and dispersion techniques also influence the measured ENM-cell interactions and can cause differences in assay results.
The presence of these factors, which are not often encountered in soluble chemical based assays, calls for assay design and standards to ensure comparability of ENM cytotoxicity assay test results among different laboratories.
One approach that has been used to identify sources of variability in analytical tests is cause-and-effect analysis (hereafter referred to as C&E analysis). C&E analysis is based on the application of measurement science to fields such as quality manufacturing and propagation of measurement error in analytical chemistry. 25 C&E analysis identifies steps within a process where modification and quality monitoring may improve the quality of the manufacturing process or a measurement test result. C&E diagrams graphically summarize the potential causes of variations in a given test method, which can help develop a strategy for gaining control over the sources of variability. Critical to using these process analysis techniques is the initial identification of sources of variability or the "causes" of the variability and their "effect" on the result of a process.
Application of C&E analysis to nanocytotoxicity assays will help identify specific control experiments that could be designed and integrated into the assay to monitor variability associated with the assay test system. While some studies have thoroughly investigated 6 ENM interferences in certain nanotoxicology assays, 24, 26, 27 potential ENM interferences are only one source of uncertainty that is assessed by C&E analysis.
Here, we specifically utilize C&E analysis to design a robust 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) cell viability assay for ENM cytotoxicity testing. The MTS assay is widely used in cytotoxicity testing, because it is one of the simplest assays with only a few major steps in the protocol and is useful for hypothesis testing. We present a prototype 96-well plate layout that incorporates a number of control experiments that assess the quality of the MTS assay system for a nano-cytotoxicity measurement, and demonstrate the application of this plate layout in a case study. The sources of variability revealed in the C&E diagram and the resulting 96-well plate layout may be generalized to other cellbased and biological assays for evaluating the environmental or human health effects of ENMs or other compounds. However, the nuances of each method need to be carefully considered with regards to how the reagents interact with the biomolecules of interest or may interact with different ENMs to identify the sources of variability for that assay.
General features of the MTS assay
The MTS assay is a "live-dead" assay where the signal is related to the number of metabolically active cells in a sample (see Figure 1 for an example summary protocol).
The absorbance at 490 nm is measured in the sample as the MTS assay reagents are converted to a purple formazan product by intracellular reductase enzymes within 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   7 rise to variability and bias in the measurement. 1 While the summary protocol shown in Figure 1 indicates a 24 h exposure time with ENM, it is important to assess cytotoxicity after multiple time periods to understand the time dependence of the toxicological effects.
When the MTS assay is used with a dose-response experimental design, the test result is typically an ED50 value, the effective dose that causes a 50 % effect. The following data analysis steps are used to generate the ED50 value: 1) Absorbance values at 490 nm are collected from wells of treated cells, non-treated cells (maximum absorbance value) and wells containing no cells (background absorbance value). 2)
Background absorbance values are subtracted from all the absorbance values from each well.
3) The background-corrected absorbance values of treated wells are then normalized to the background corrected absorbance values of the non-treated cell samples. After these calculations, a normalized absorption value near 1 is typically interpreted as no effect of the treatment condition on the cells whereas a measurement of 0 represents a complete toxic event where no viable cells remain in the cell culture well. 4) The normalized absorbance values are then fitted to a sigmoid dose-response curve and the ED50 value for the curve is calculated. 28 Three or more replicate doseresponse curves are used to evaluate the variability of the ED50 value.
Cause-and-effect analysis of the MTS assay
The example summary protocol for an MTS cell viability assay for ENM shown in Figure 1 was used to generate a C&E diagram. We identified major categories for sources of variability in the test result based on the steps on the summary protocol (Table 1) . Major categories for sources of variability (i.e., pipetting) 29 can impact many 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 8 steps in the protocol and are considered the main branches of the C&E diagram ( Figure   2 ). Additional details about the contributory factors that may introduce variability in the assay result are then added to each of the main branches (Figure 2 ). These factors can be found in the manufacturer's protocol, other high-quality protocols, expert opinion, and best-practice guidance documents. 2 The final goal is to add as many reasonable factors that may influence the assay result while minimizing the number of factors that have a negligible effect on the measurement readout (i.e., plate reader manufacturer). After identification of important factors, control experiments were designed to assess the variability in these factors. The results of these control experiments serve to establish quality parameters that can be tracked with control charts to ensure confidence in the test measurement system.
Design of 96-well plate MTS assay
The control experiments identified during the C&E analysis of the MTS assay were incorporated in a novel 96-well plate layout (see Figure 3 ). In the 96-well plate layout, only 18 wells (Feature 8, Figure 3 ) correspond to the actual test samples, which are used to investigate dose-dependent effects of ENM on cell viability. The remaining 78 wells on the 96-well plate serve as seven system control experiments for qualifying the reliability, reproducibility and comparability of the test measurement. The ENM dose concentrations are multiples of the best guess concentration (BG) for the ED50 value obtained from preliminary experiments or literature values. When choosing the concentrations, it is advisable to include one concentration which elicits no effect, one concentration which elicits a complete effect, and several concentrations which elicit effects on the transition part of the ED50 curve. 30 Judicious choices for the test concentrations will help minimize the uncertainty due to fitting the ED50 value. 
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Measurements from these control experiments should be charted over time to characterize the natural variability of the test system. Specifications based on the control charts can then be used to define the acceptable operating range of the MTS test system. For each assay, the results from the control experiments must be within the predefined specifications for a valid ENM test result.
Cause and Effect Diagram and Control Experiments for the MTS Assay
Branch 1-Variability due to cell maintenance. Although cell culture is routinely performed in laboratories, many factors that can give rise to variability in ENM cytotoxicity results are not frequently reported. Cell culturing factors that may influence the ENM test results include thaw passage number, passage number at the time of experiment, experimental and passaging cell seeding density, and cell passaging procedures in general including cell detachment techniques, and variability in uncontrolled substances such as fetal bovine serum (FBS) (see Table 1 and Figure 2) . 3 In addition, the identity of the original cells may be questionable if the DNA integrity has not been confirmed.
The following steps can be taken to address these potential sources of variability.
At a minimum, it is critical to document the cell culture handling and maintenance procedures in great detail. This ensures that the steps can be repeated at a later time or in a different laboratory. This documentation can also be used to identify other sources of variability in cell-based nanotoxicity assays. For example, if there is a systematic change in a control experiments and the test result, documentation can be used to assess if a change FBS serum lots or manufacturer could be the source of the change in the control experiment results. Assuring the DNA integrity in cells used in cell-based assays is critical given recent high profile reporting on the prevalence of contaminated or misidentified cell lines. 31 This can be performed using DNA integrity tests, which are commercially available for human cell lines and have been recently developed for mouse and vervet monkey, 32, 33 before initiating experiments. These tests function by confirming retention of short-nucleotide tandem repeats (STR) within the genomic DNA and are relatively rapid and highly confirmatory. 34 Changes in the STR results can indicate cell line contamination, changes in chromosome structure, or chromosome deletions, all of which can lead to variability in the ENM test result.
Cell line characteristics can also be specified and monitored such as the calculated proliferation rate, isoenzyme analysis for species verification (ATCC) and two-dimensional projected morphology. 35 Each of these parameters is sensitive to culture conditions, cell contamination, extracellular matrix, and cell handling conditions. Ideally, all of these cell-assay specific factors should be documented, but practically, the benefit of these tests should be weighed against expert opinion before they are specifically described in the testing protocol for improving reliability in the ENM cell assay.
The 96-well plate layout includes a non-treatment cell control experiment 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Control experiments to assess within-pipette channel variability, betweenpipetting step variability, and evidence of pipette maintenance/technique can substantially improve assay reliability. An advantage of using a multi-channel pipette is that the regularity of the cell seeding density across the pipettes is likely governed by the homogeneity of the suspended cells before they are picked up with the individual pipettes, and the calibration of each pipette channel volume. For well-maintained multichannel pipettes it is likely that within-pipette channel variability in cell seeding density is significantly lower than the variability between separate pipetting steps due to cell settling and resuspension requirements. Figure 3 shows an example of a 6-channel pipette and a recommended orientation for cell seeding. By seeding each column with a single pipette ejection, variability in seeding density between the nontreatment and treatment wells for a single dose-response replicate is likely minimized.
This can reduce variability in the determination of the ED50 values for the assay.
Two control experiments (Features 1 and 2 in Figure 3 ) introduced into the 96-well plate layout assess pipetting-specific issues based on cell seeding column-wise into the 96-well plate using a multichannel pipette (6-channels at a time). Feature 1 can be used to measure the within multichannel pipette variation. Feature 2 serves as a control for variability between multichannel pipetting steps. The mean absolute absorbance 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   12 values and the variability of these wells after MTS reagent addition should be charted.
This allows identifying trends that can indicate a malfunction of the multichannel pipette or a change in the pipetting technique. Data from these control experiments allow evaluation of the quality in the pipetting steps. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 13 these controls are intended to detect such problems, they do not necessarily provide sufficient information to identify the source of the problem. If the variability exceeds a specification-based threshold, further experiments would be required to identify the experimental factor that is not performing as expected. Furthermore, these controls do not directly evaluate the linearity of the instrument response or the possibility of inaccurate measurements in particular wells. Experiments to assess these particular controls can also be performed using plates with absorbance standards. An appropriate chemical control is highly stable, antibacterial, can be accurately and reproducibly prepared, has a cytotoxic mechanism that is general to many different types of cells, and its concentration can be readily quantified in solution. 36, 37 A metal 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 14 salt, such as CdCl2, fits these criteria. At high concentrations, CdCl2 is antibacterial, stable at mM stock concentrations in water for long periods of time, concentration can be measured using several widely available analytical techniques (e.g., ICP-OES), and is toxic to many types of cells. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Thus, control experiments to monitor reagent quality will help ensure confidence in assay results. The manufacturing specifications (e.g., lot number), storage conditions, and the results of these control measurements should be documented.
A novel and critical consideration for using toxicity assays requiring chemical reagents is that ENM may interact with the reagents and cause false positive or false negative results. 19, 21, 22, 26, 38 For the MTS assay, it is important to determine that the nanoparticle being tested does not directly affect the MTS reagent optical properties in the absence of cells, change the background absorbance through ENM precipitation in the well, or adsorb the reagent. 19, 22 The 96-well plate design (Figure 3 Removing the supernatant after cell treatment or washing, and before MTS reagent application may introduce another source of variability in the assay process. As 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 the signaling pathways that lead to toxicity are (at least initially) unknown, it might be possible that cells start detaching from the culture plate before actually dying. Thus, cells that are only loosely attached to the cell culture plate, but still viable may be removed with the supernatant and are thus missing in the final measurement. Rigorous rinsing will lead to the loss of more cells than gentle rinsing and this would lead to labto-lab or experiment-to-experiment variations. Development of a highly reproducible rinsing protocol and clear articulation of the protocol in the assay procedure can reduce this variability. This variability is can be evaluated by many of the pipetting controls described above.
Curve fitting and parameterization of the dose-response curve for both the positive chemical control and the ENM viability test also give rise to variability.
Different algorithms can lead to different results. A clear indication of how curve fitting
was accomplished should be reported with the value of the test result. The accuracy of the curve fitting can be improved by using a dosing strategy that includes a notreatment response and a maximum dose response and other dosing concentrations that cover as much of the transition between the minimum and maximum response as possible. 30 Fitting errors in the estimation of the ED50 value with a logistic curve can be significant if there are few or no dose points that aid in defining the logistic curve transition. 39 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Branch 6 -Variability due to nanoparticle handling and characterization. Stock ENM suspensions need to be evaluated to ensure that they have the expected physicochemical characteristics such as morphology, zeta-potential, size, size distribution, surface activity and composition. 6 In addition, ENM often contain additional substances such as impurities (metal catalysts or endotoxins) and other molecules that improve the stability of the ENM dispersion (surface coatings, detergents, etc.). Thus, the toxicity of several compounds is typically being tested at once and careful experiment design is needed to distinguish between effects caused by these additional chemicals and those from the ENM itself. 5 Moreover, preparation of ENM dispersions, such as the dispersion of fullerenes using tetrahydrofuran, can cause artifacts in nanotoxicology assays. 40, 41 Preparation of the final working concentration of ENM dispersed in biological media is an additional source of variability in the ENM branch of the cause-and-effect diagram. The unique physico-chemical properties of ENM can cause them to behave as colloids and not as fully dissolved chemical compounds. Effects such as agglomeration, precipitation, and particle dissolution can occur within the ENM dispersion, and this changes the nature of the dosing treatment over the time course of the toxicity experiment. The extent of these effects can be greatly influenced by the method used to disperse the nanoparticles (i.e., sonication, stirring, vortexing, etc.) and the type of dispersion media. [42] [43] [44] Characterization of the dispersion must be performed throughout the time of the toxicity experiment to ensure that these characteristics and exposure dose are reproducible and accurate. 45, 46 Sonication power, stirring speed, time after the addition of ENM, time after dispersion before cell treatment, ionic strength of the biological media, and the presence of serum protein should be controlled and reported to ensure reproducible particle dispersions. While several studies have suggested 18 methods to disperse ENM, 43, 45, 46 it is likely that each ENM will require testing for dispersion procedure development. It is important to note that a high-quality MTS assay does not require a well-dispersed primary ENM. Even if a final ENM dispersion exhibits agglomeration or dissolution, the reproducibility of the dispersion technique can be established and the specific procedure included in the assay protocol. Both the treatment volumes and the dosing concentration should be clearly described in the assay protocol so that the total number of particles or total ENM mass in the treatment well can be estimated. This enables calculating toxicity values using ENM mass or number concentration metrics.
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Case Study
A case study was conducted using positively charged polystyrene nanoparticles (PS-NPs) to demonstrate the applicability of the plate layout; nanoparticles are a class of ENMs with all three dimensions less than 100 nm. The method used to conduct the case study and the raw data from the case study (Tables S1 and S2 ) are provided in the Supporting Information. This method follows the general steps described in Figure 1 but contains substantially more detail. The results from the case study are shown in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Conclusions
The presence of contradictory test results from cell-based assays in nanotoxicology journals has been described in several reviews. 6, 14 To systematically define the significant sources of variability in a nanocytotoxicity assay, we applied C&E analysis to assess the MTS assay for use with ENM and performed a case study. It is important to note that C&E analysis does not provide quantitative information on the nominal variability in these cause factors and the size of the effect these factors have on the test result. C&E diagrams are a highly ordered approach for cataloging sources of variability. Using this C&E diagrams we designed a novel 96-well plate layout for the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   20 MTS assay, which consists of 7 system control measurements in addition to the ENM test result (see Figure 3) . By monitoring or charting of the results from these control experiments for instrument, assay reagent, cell seeding density and positive chemical control performance, we generate a graphical tool (i.e., chart) that enables performance assessment of the assay measurement system. Continued monitoring of the assay performance serves multiple functions: 1) highlighting unexpected trends in the control data, 2) supporting rapid identification of outlier results indicative of changes in the assay system, 3) enabling comparison of assay performance within and between laboratories and for each measurement performed by a scientist, and 4) providing confidence checks on the test ENM results. A test ENM result should only be considered valid when all of the control parameters lie within specifications defined by the charting process. If the control measurements do not meet specification, issues such as pipette calibration, chemical and MTS reagent quality, cell quality and instrument quality should be tested and corrected. This approach also facilitates sensitivity assessment of assays in which the magnitude of variation caused by different factors is tested.
Overall, the development of a C&E diagram for an assay is a useful strategy for understanding the factors that can affect assay performance resulting in noncomparable test results. Although the diagram shown in Figure 2 is based on the MTS assay, it is likely that similar cause-and-effect diagrams are applicable to many cytotoxicity assays. The data generated in the case study indicate how assay specifications can be developed using the 96-well plate design. The use of such a protocol in an interlaboratory comparison can provide further insight into the parts of the protocol that require more detailed procedures to reduce large variabilities observed in the control measurements between the laboratories. This plate design is 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   21 currently being used to develop a high quality protocol that allows comparability of nanocytotoxicity data among international laboratories.
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